Loading clinical trials...

Impact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmatic Patients Followed at Poitiers University Hospital on Biotherapy | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATION

Impact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmatic Patients Followed at Poitiers University Hospital on Biotherapy

NCT06916104•Poitiers University Hospital

View on ClinicalTrials.gov

Summary

The aim of this study is to take stock of the situation of adult patients with severe asthma on biotherapy, followed up at Poitiers University Hospital, and in particular to increase our knowledge of factors predictive of response to biotherapy. The main aim is to improve the management of adult severe asthma patients treated with biotherapy, according to their allergic status.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Severe asthma patient on biotherapy
•Age \> or = 18 years
•Follow-up at Poitiers University Hospital

Exclusion Criteria

•Absence of allergological assessment
•Patient's refusal to participate in study

Locations (1)

Chu Poitiers

Poitiers, France

Key Dates

Start Date

March 1, 2024

Primary Completion Date

March 31, 2025

Completion Date

March 31, 2025

Last Updated

April 8, 2025

Enrollment

100

ESTIMATED participants

Conditions

Severe AsthmaBiotherapyRespiratory Allergy

Interventions

search for respiratory allergies

OTHER

Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department

NCT05691218

Moderate Asthma ExacerbationSevere Asthma Exacerbation

View study

RECRUITING

Exploring the Lived Experience of Young Adults With Severe Asthma

NCT06681545

AsthmaSevere Asthma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmatic Patients Followed at Poitiers University Hospital on Biotherapy

Inclusion Criteria

Exclusion Criteria

Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department

Exploring the Lived Experience of Young Adults With Severe Asthma

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

Phase II Trial of RC1416 Injection in Asthma

Remission in Adults With Severe Asthma in Thailand